Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall Millikan

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Oncology (Williston Park, N.Y.)|July 11, 2002
Docetaxel in the management of advanced or metastatic urothelial tract cancerChristopher Logothetis, Randall Millikan
Urologic Oncology|December 31, 2002
Pilot study of sequentially applied doublets in poor-prognosis metastatic urothelial cancerDallas Williams, Randall Millikan
Urologic Oncology|December 25, 2003
Neoadjuvant chemotherapy for bladder cancerRandall Millikan, Arlene Siefker-Radtke, H Barton Grossman
Cancer Research|December 18, 2004
Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cellsAngela Papageorgiou, Laura Lashinger, Randall Millikan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancerRandall Millikan, Peter F Thall, Sang-Joon Lee, et al.
The Journal of Urology|January 10, 2004
Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapyJoel W Slaton, Randall Millikan, Keiji Inoue, et al.
Molecular Cancer Therapeutics|March 18, 2004
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivoAshish M Kamat, Takashi Karashima, Darren W Davis, et al.
Cancer|June 22, 2010
Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinomaSurena F Matin, Vitaly Margulis, Ashish Kamat, et al.
The Journal of Urology|May 29, 2003
Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?Paul Sweeney, Randall Millikan, Machelle Donat, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Oncology (Williston Park, N.Y.)|July 11, 2002
Docetaxel in the management of advanced or metastatic urothelial tract cancerChristopher Logothetis, Randall Millikan
Urologic Oncology|December 31, 2002
Pilot study of sequentially applied doublets in poor-prognosis metastatic urothelial cancerDallas Williams, Randall Millikan
Urologic Oncology|December 25, 2003
Neoadjuvant chemotherapy for bladder cancerRandall Millikan, Arlene Siefker-Radtke, H Barton Grossman
Cancer Research|December 18, 2004
Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cellsAngela Papageorgiou, Laura Lashinger, Randall Millikan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancerRandall Millikan, Peter F Thall, Sang-Joon Lee, et al.
The Journal of Urology|January 10, 2004
Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapyJoel W Slaton, Randall Millikan, Keiji Inoue, et al.
Molecular Cancer Therapeutics|March 18, 2004
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivoAshish M Kamat, Takashi Karashima, Darren W Davis, et al.
Cancer|June 22, 2010
Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinomaSurena F Matin, Vitaly Margulis, Ashish Kamat, et al.
The Journal of Urology|May 29, 2003
Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?Paul Sweeney, Randall Millikan, Machelle Donat, et al.
Pageof 1